• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO CORPORATION IMUFLEX BLOOD BAG SYSTEM; IMUFLEX WB-RP BLOOD BAG SYSTEM WITH LR FILTER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO CORPORATION IMUFLEX BLOOD BAG SYSTEM; IMUFLEX WB-RP BLOOD BAG SYSTEM WITH LR FILTER Back to Search Results
Catalog Number 1BBWGQ506A2
Device Problems Restricted Flow rate (1248); High Test Results (2457); Filtration Problem (2941)
Patient Problem No Patient Involvement (2645)
Event Date 02/07/2020
Event Type  malfunction  
Manufacturer Narrative
Investigation is in process.A follow-up report will be provided.
 
Event Description
The customer reported elevated white blood cell (wbc) content in a filtered whole blood unit.There was not a transfusion recipient or patient involved at the time of whole blood processing, therefore no patient information is reasonably known at the time of the event.Donor unit #: (b)(6).Terumo bct is awaiting return of the disposable set.
 
Manufacturer Narrative
This report is being filed to provide additional information in d.10, h.3, h.6 and h.10.Investigation: one set of blood bags with the filter from the collection set was returned for evaluation.The leukoreduction filter was tested for flow rate and air leaks.A fast flow rate of 55ml/min was noted, and it was confirmed there were no air leaks.The filter was disassembled to observe the appearance of filter membranes and noticed creases in the filter membranes of the filter.The creases in the filter were not different from those in conforming products and in the filter membranes and no aggregation was observed in any filter membranes.The sixth filter membrane showed a white color at the top of the inflow side, that is, blood had hardly flowed through the membrane.The manufacturing records, test records, and inspection records were reviewed for abnormalities and none were found.The records regarding the particulate removal rates of the filter membranes were reviewed.All membranes conformed to established specification.Shipping testing was performed on the reserve samples from the reported lot number.The reserve samples were also visually examined, and the solution volume and solution composition were tested with no abnormalities noted.All product conformed to the established specification.Root cause: control to maintain cationization levels above a certain level during the production of filter membranes in order to prevent from leukocyte leakage.Where a cationization level is high, filtration rate is likely to be low.For the prevention of leukocyte leakage, the instructions for use of the product state: "[caution] do not squeeze or apply pressure on the filter while it is attached to the bag containing the filtered blood", and "clamp the blood filled tubing before blood enters the filter".The above-mentioned investigation results revealed that there were no abnormalities in the manufacturing record and the testing and inspection record of the reported lot number.The returned filter also revealed no abnormalities in themselves.It was noticed that all the filter membranes were locally dyed dark with toluidine blue.Therefore, occlusion may have occurred and blood may have been filtered by the filter area which was smaller than usual and the linear speed (flow rate per unit area) increased, and then leukocyte leakage occurred.It was observed no aggregation in any filter membranes and confirmed an area of the filter membrane that had not been used for filtration.It was likely to take a longer time for priming of the filter for some reason; however, we were not able to identify the cause of the issue.It was inferred that the unused areas of the filter membrane impeded blood flow and it caused to increase the linear speed of the areas where blood flowed.As a result, leukocyte leakage may have occurred.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IMUFLEX BLOOD BAG SYSTEM
Type of Device
IMUFLEX WB-RP BLOOD BAG SYSTEM WITH LR FILTER
Manufacturer (Section D)
TERUMO CORPORATION
fujinomiya
MDR Report Key9827490
MDR Text Key185769706
Report Number9681839-2020-00017
Device Sequence Number1
Product Code CAK
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Type of Report Initial,Followup
Report Date 03/12/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date12/31/2021
Device Catalogue Number1BBWGQ506A2
Device Lot Number190718AF
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer02/18/2020
Was the Report Sent to FDA? Yes
Initial Date Manufacturer Received 02/18/2020
Initial Date FDA Received03/12/2020
Supplement Dates Manufacturer Received03/11/2020
Supplement Dates FDA Received03/26/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Other;
-
-